Participants will either receive the vaccine or a placebo. They will be tracked for two years to see whether they get COVID-19 or have any adverse reactions to the vaccine.
Foxx Life Sciences' VersaCap® technology is seen used in a lab in the segment above. VersaCap® eliminates the risk of pouring high-value substances with top quality Caps and Adapters. The caps are compatible with a wide range of adapter inserts that feature a leak-proof design. These caps and adapters are ideally used for liquid handling and transfer applications in industries like pharmaceuticals and biotechnology. All caps are Class VI, BSE Free, and have passed USP 665 L&E testing. Available in 38-430, GL45, 53B, 83B, and 120mm sizes!
Article Source: https://www.nbcnews.com/health/health-news/covid-19-vaccine-moderna-begin-final-human-trial-end-july-n1233788